Cured by blood: the hidden healing powers circulating inside you

Blood is one of science’s most complex substances. It carries hundreds of proteins, immune cells, hormones, and signalling molecules that work in concert to maintain the body’s equilibrium. An article titled ‘Cured by blood’, published in April 2026 in Science, highlights a striking phenomenon: in certain conditions, blood itself — or specific fractions of it — can exert a direct healing effect. Not through the standard immune response, but through mechanisms that operate independently of white blood cells. Certain blood proteins appear capable of killing bacteria and parasites on their own.

This connects to one of the most discussed threads in longevity science: the idea that blood composition changes dramatically with age. Young blood contains factors that appear to slow cellular aging; old blood contains pro-inflammatory molecules that seem to accelerate it. The famous parabiosis experiments — in which young and old mice shared a circulatory system — showed that old tissue rejuvenated when exposed to young blood. Which molecules are responsible remains fiercely debated.

The search for what actually works

Scientists have spent years trying to isolate the specific molecules responsible for blood’s rejuvenating effects. Candidates like GDF11, klotho, and various microRNAs have appeared repeatedly in the literature, though some early findings have since been questioned. The new Science article adds another layer: it describes how blood components can intervene in infections and acute tissue damage through pathways outside classical immunity. That makes blood a kind of multifaceted pharmaceutical library we are only beginning to decode.

For aging research, this matters because aging is characterised by chronic low-grade inflammation — a state researchers call inflammaging. If specific blood components can dampen or reverse that inflammation, they become attractive targets for intervention. Plasma treatments, in which plasma from young donors is administered to older patients, are already being tested in small clinical studies. The regulatory and ethical questions are enormous, but the biological rationale keeps getting stronger.

From laboratory curiosity to clinical reality

Translating these insights into safe treatments is not straightforward. Blood is so complex that isolating one molecule responsible for a specific effect is enormously difficult. And what works in a mouse or a laboratory setting does not automatically translate to an aging human body. Some early plasma therapy trials have produced disappointing results, or results that are hard to interpret. Whether the future lies in whole plasma transfusions, isolated proteins, or entirely synthetic mimics remains an open question — and probably not one that will be settled soon.

Read the original article